Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2026 | $5.00 | Buy | B. Riley Securities |
| 12/3/2025 | $5.50 | Buy | Roth Capital |
8-K - Microbot Medical Inc. (0000883975) (Filer)
8-K - Microbot Medical Inc. (0000883975) (Filer)
8-K - Microbot Medical Inc. (0000883975) (Filer)
HINGHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, will be participating at this year’s Society of Robotic Surgery (SRS) annual meeting, being held from July 23-26, in Fort Lauderdale, FL. Last year’s meeting was the first time that endovascular robotics was featured at SRS, and with the Company’s FDA clearance less than a year ago and the growing adoption of the LIBERTY System at leading academic centers in the U.S. for a broad range of peripheral endovascular procedures, the Company believes the continued focus on this segment of the market underscores its increasing impo
The Company is experiencing rising demand and increasing pipeline for the LIBERTY System since commencing the Full Market Release in April Heightened awareness generating interest from leading health systems across the U.S. as Company plans to increase its U.S. sales territories from 8 to 12 and enter international markets by the end of 2026 HINGHAM, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, is reporting greater than 100% growth in revenue and new customers for the second quarter ended June 30, 2026, compared to the first quarter ended March 31, 2026. The performance ref
HINGHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into a Letter of Agreement (LOA) with Sanmina Corporation, a leading global integrated manufacturing solutions provider, to manufacture the LIBERTY System, the only FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. As momentum continues to rise in the U.S., reflected in increased accounts and usage across several states, and with the momentum building in the international markets as seen with the recent clearance in Israel and progress towards obtaining CE Mark as w
4 - Microbot Medical Inc. (0000883975) (Issuer)
4 - Microbot Medical Inc. (0000883975) (Issuer)
4 - Microbot Medical Inc. (0000883975) (Issuer)
B. Riley Securities initiated coverage of Microbot Medical with a rating of Buy and set a new price target of $5.00
Roth Capital initiated coverage of Microbot Medical with a rating of Buy and set a new price target of $5.50
HINGHAM, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into an agreement with Lovell® Government Services to serve federal healthcare systems, such as those administered by the Veterans Health Administration (VHA), a division of the U.S. Department of Veteran Affairs, the Military Health System (MHS), which is run by the U.S. Department of Defense, and the U.S. Indian Health Service (IHS). Lovell Government Services will become Company's Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor to serve these customers through federal contracting systems. Lovel
Commercial adoption of the LIBERTY System by sites that participated in the clinical trial serves as a strong validation of the value it brings to everyday practice The Company will attend the Annual Global Embolization Symposium & Technologies (GEST), a Premier Medical Conference in New York City that attracts over 1,000 global experts across key target call points HINGHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, which is experiencing strong interest from physicians and hospital executives following the commencement of the Full Market Release of LIBERTY at the recent Soc
Commencement of activities in international markets is supported by the successful completion of the Limited Market Release, followed by the Recent Full Market Release in the U.S. Strong physician interest at recent Society of Interventional Radiology conference and rising awareness across markets outside the U.S. supports commercial readiness throughout heavily populated regions HINGHAM, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, is continuing to implement its growth strategy with the appointment of Alon Tamir as Vice President of Sales, Europe, the Middle East and Asia
Conference call and live webcast to be held Monday, May 18th at 3:00pm ET Wall Street firm publishes research report refuting claims made by recent unaffiliated third-party article; Research report also references Vascular Surgeon who categorically disputes many of the assertions that were attributed to him in same unaffiliated third-party article Company to review claims made in the unaffiliated third-party article, to correct certain misleading statements and misrepresentations to ensure the investing public is fully informed of the actual facts HINGHAM, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® E
SC 13G/A - Microbot Medical Inc. (0000883975) (Subject)
SC 13G - Microbot Medical Inc. (0000883975) (Subject)